Showing 2,281 - 2,300 results of 8,630 for search 'significantly ((((lower decrease) OR (((we decrease) OR (nn decrease))))) OR (teer decrease))', query time: 0.44s Refine Results
  1. 2281

    The result of molecular dynamics simulation. by Ashraf Attia Mahmoud (21262201)

    Published 2025
    “…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”
  2. 2282

    Result of the phenotypic analysis. by Ashraf Attia Mahmoud (21262201)

    Published 2025
    “…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”
  3. 2283

    Type of Mutations. by Ashraf Attia Mahmoud (21262201)

    Published 2025
    “…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”
  4. 2284

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  5. 2285

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  6. 2286

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  7. 2287

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  8. 2288

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  9. 2289
  10. 2290

    Baseline analysis, nominal factors. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  11. 2291

    Minimal dataset for the study. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  12. 2292

    Baseline analysis, continuous factors. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  13. 2293

    Multivariable analysis between 2006 and 2018. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  14. 2294

    <b> </b> Energy efficiency and gas volume comparison. by Ning Zuo (17295415)

    Published 2025
    “…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
  15. 2295

    Model validation of kinetic parameters. by Ning Zuo (17295415)

    Published 2025
    “…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
  16. 2296
  17. 2297
  18. 2298
  19. 2299

    Graphical abstract regarding program development. by Ana Beato (20489933)

    Published 2024
    “…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”
  20. 2300

    Phases of the intervention program. by Ana Beato (20489933)

    Published 2024
    “…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”